[Mr 1268--a new furylmethyl-substituted benzomorphan. Comparison of its effects with pentazocine and placebo in a double-blind study].
Mr 1268 (alpha-5,9-dimethyl-2(3-methyl-3-methylfuryl)-2-hydroxy-6, 7-benzomorphan) was tested in two dosages (15 mg and 30 mg) at random on a total of 200 patients with severe postoperative pain in a double blind study against pentazocine and placebo. The analgesic effect of 30 mg Mr 1268 and 30 mg pentazocine compared with placebo was statistically significant 15 min after intramuscular injection. At the dosage applied no major respiratory or circulatory effects were observed in the patients. The minimal changes in the systolic blood pressure were of no statistical significance. Side-effects observed in many patients in the verum group were miosis and transpiration. For all other side-effects there was no statistically significant difference between placebo and the verum group or among the various verum groups.
D000328:Adult; D000368:Aged; D000700:Analgesics / Q000627:therapeutic use*; D001575:Benzomorphans / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009019:Morphinans / Q000627:therapeutic use*; D010149:Postoperative Pain / Q000188:drug therapy*; D010423:Pentazocine / Q000627:therapeutic use*; D010919:Placebos; D013997:Time Factors
D000700:Analgesics; D001575:Benzomorphans; D009019:Morphinans; D010919:Placebos; C033491:Mr 1268; D010423:Pentazocine
Mr 1268--ein neues Furylmethyl substituiertes Benzomorphan. Wirkungsvergleich mit Pentazocin und Placebo im Doppelblindversuch.